Valuation: Merck & Co., Inc.

Capitalization 275B 234B 214B 202B 377B 25,980B 380B 2,537B 989B 12,479B 1,032B 1,010B 43,084B P/E ratio 2026 *
49.7x
P/E ratio 2027 * 13.4x
Enterprise value 310B 263B 241B 227B 424B 29,252B 428B 2,857B 1,114B 14,051B 1,162B 1,138B 48,510B EV / Sales 2026 *
4.63x
EV / Sales 2027 * 4.22x
Free-Float
68.99%
Yield 2026 *
2.99%
Yield 2027 * 3.11%
1 day-0.82%
1 week-0.70%
Current month+2.02%
1 month-9.21%
3 months-5.33%
6 months+29.09%
Current year+5.81%
1 week 110.75
Extreme 110.75
114.62
1 month 107.9
Extreme 107.9
121.3
Current year 104.43
Extreme 104.43
125.14
1 year 73.31
Extreme 73.31
125.14
3 years 73.31
Extreme 73.31
134.63
5 years 70.89
Extreme 70.89
134.63
10 years 52.83
Extreme 52.83
134.63
Manager TitleAgeSince
Chief Executive Officer 59 2021-06-30
Director of Finance/CFO 57 2021-03-31
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 65 2007-11-26
Director/Board Member 73 1995-08-31
Chairman 59 2022-11-30
Change 5d. change 1-year change 3-years change Capi.($)
-0.82%-0.70%+46.61%-5.15% 275B
-2.72%-1.54%+29.12%+121.40% 846B
-0.53%-2.58%+43.51%+37.42% 533B
-0.57%-2.44%+9.18%+37.27% 356B
-0.94%-0.97%+22.40%+11.18% 324B
+0.23%-1.24%+30.31%+12.00% 282B
+0.05%-2.19%+24.69%+21.29% 278B
-1.76%+4.42%-34.66%-49.15% 203B
+0.79%+0.57%+24.76%+41.49% 179B
-2.04%-0.24%+35.52%+66.66% 163B
Average -0.83%-0.69%+23.14%+29.44% 343.84B
Weighted average by Cap. -1.10%-1.22%+26.11%+45.29%

Financials

2026 *2027 *
Net sales 66.85B 56.8B 51.98B 49.06B 91.51B 6,313B 92.32B 617B 240B 3,033B 251B 246B 10,470B 70.37B 59.79B 54.72B 51.64B 96.33B 6,646B 97.18B 649B 253B 3,192B 264B 258B 11,021B
Net income 5.56B 4.72B 4.32B 4.08B 7.61B 525B 7.67B 51.24B 19.98B 252B 20.84B 20.41B 870B 20.43B 17.35B 15.88B 14.99B 27.96B 1,929B 28.21B 188B 73.44B 927B 76.63B 75.02B 3,199B
Net Debt 34.65B 29.44B 26.94B 25.43B 47.43B 3,272B 47.85B 320B 125B 1,572B 130B 127B 5,426B 21.59B 18.34B 16.79B 15.85B 29.56B 2,039B 29.82B 199B 77.63B 979B 81B 79.3B 3,382B
Logo Merck & Co., Inc.
Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (73.9%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of vaccines (15.5%); - sale of animal health products (9.8%); - other (0.8%). Net sales are distributed geographically as follows: the United States (56.2%), Europe/Middle East/Africa (22.4%), Latin America (5.2%), Asia/Pacific (4.6%), Japan (4.2%), China (3%) and other (4.4%).
Employees
74,000
Calendar
05-14 -
Date Price Change Volume
26-05-08 111.38 $ -0.82% 5,725,143
26-05-07 112.30 $ -1.11% 7,329,028
26-05-06 113.56 $ +0.36% 7,256,078
26-05-05 113.15 $ +0.04% 7,910,399
26-05-04 113.11 $ +0.85% 7,659,082
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
111.38USD
Average target price
129.74USD
Spread / Average Target
+16.48%

Quarterly revenue - Rate of surprise